Topiroxostat

Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%) . Topiroxostat has the potential for hyperuricemia treatment[1][2].

Product Specifications

CAS Number

[577778-58-6]

Product Name Alternative

FYX-051

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450; Xanthine Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Topiroxostat.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 23.5 mg/mL (ultrasonic; warming)

Smiles

N#CC1=NC=CC(C2=NNC(C3=CC=NC=C3)=N2)=C1

Molecular Formula

C13H8N6

Molecular Weight

248.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Sato T, et al. Discovery of 3- (2-cyano-4-pyridyl) -5- (4-pyridyl) -1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19 (21) :6225-9.|[2]Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336 (1) :95-103.